Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030794 (pelvic pain)
 4,056 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Primary dysmenorrhea is a difficult entity to treat, and therapy is usually directed at relieving symptoms. There is some indication that this disorder is caused by an increase in prostaglandin F2alpha. Therefore, logically the treatment may include antiprostaglandin agents. We have studied 32 women with the diagnosis of primary dysmenorrhea in a randomized double-blind fashion using a placebo and indomethacin. Both agents were taken three times a day over four cycles, and therapy was begun two days before the usual onset of pelvic pain. Only two of 16 patients in the placebo group were significantly improved in the four-month treatment cycles while all 16 in the treatment group showed some improvement, 11 having cessation of pain. In the six months following the study period, all patients were given indomethacin. The original treatment group did not change significantly. However, all in the placebo group when switched to indomethacin had some relief, 12 of the 16 showing complete cessation of pain. Gastric irritation was the main side effect and was present in 18% of the treatment group and 12% in the placebo group. Indomethacin appears to effectively relieve primary dysmenorrhea and does not appear to be associated with a high incidence of side effects.
 ...
PMID:Primary dysmenorrhea treated with indomethacin. 37 24

From April 1, 1995, to December 31, 1995, 45 patients undergoing diagnostic or operative laparoscopy for infertility, pelvic pain, or both, were found to have endometriosis. No woman had undergone any preoperative medical or surgical treatment for the disease. Preoperatively they answered a questionnaire, including a visual analog scale (VAS) to evaluate their associated symptoms. All visible signs of endometriosis were evaluated at laparoscopy by a single observer and recorded. Endometriosis was classified as cysts, adhesions, typical implants (black-blue powder burn implants), and atypical implants (clear papules, red polyps, flamelike lesions, red-brown vesicles, white opacification, peritoneal defects). The revised American Fertility Society (AFS) score was also used to stage the disease. The VAS scale for dysmenorrhea correlated significantly with the AFS total score (Pearson's r = 0.510, p <0.001), the cyst subscore (r = 0.490, p <0.001), and the adhesion subscore (r = 0.381, p <0.01). There was no correlation between the VAS scale for dysmenorrhea and the AFS implant subscore (r = 0.019), or with the total number of endometriosis implants (r = 0.160), the number of typical implants (r = 0.025), or the number of atypical implants (r = 0.161). The AFS score for endometriosis, devised primarily to formulate a prognosis in infertile women, seems to be correlated also with endometriosis-associated dysmenorrhea. Although atypical implants produce higher amounts of prostaglandin F2alpha compared with typical implants, the present study does not support the suggested association between them and the severity of dysmenorrhea.
 ...
PMID:Endometriosis-Associated Dysmenorrhea Is Not Related to Typical or Atypical Peritoneal Implants 907 89